SAGA represented in oral presentations at AACR and ASCO annual meetings and in a peer reviewed article
LUND, Sweden – /May 28, 2020/ – SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces recent breast cancer research results recognized at leading international cancer research and oncology conferences, AACR and ASCO, and a leukemia study published in Leukemia & Lymphoma.
The participation of SAGA Diagnostics’ team members in these three scientific projects, and their positive review and selection and recognition by top quality peers, exemplifies the high standards that we hold for ourselves at SAGA.
– Lao Saal, CEO of SAGA Diagnostics.
ASCO Annual Meeting: SAGA Diagnostics senior bioinformatician Christian Brüffer’s work has been selected for a poster discussion session at the upcoming American Society for Clinical Oncology Annual Meeting (May 29-31). The work describes the mutational landscape of 3217 primary breast cancers through RNA-sequencing within the SCAN-B network. Other SAGA contributors include scientist Yilun Chen, Chief Technical Officer Anthony George, and Chief Executive Officer Lao Saal. Read more at https://meetinglibrary.asco.org/record/188474/abstract
AACR Annual Meeting: Research by Malin Dahlgren and colleagues was selected for a prestigious oral presentation at the American Association for Cancer Research Annual Meeting 2020. Her presentation, given April 27 and available online, describes the identification of rare but significant ESR1 mutations in primary breast cancers, present in the cancers prior to any therapy, which predicted eventual poor outcomes to endocrine therapy. ESR1 mutations were verified using SAGAsafe® technology, and the study involved SAGA Diagnostics team members Anthony George, Christian Brueffer, Yilun Chen, and Lao Saal. Read more at https://www.abstractsonline.com/pp8/#!/9045/presentation/10776
Acute myeloid leukemia: Research utilizing ultrasensitive SAGAsafe® assays for minimal residual disease (MRD) monitoring in AML has recently been published in the journal Leukemia & Lymphoma (open access). Authored by Louise Pettersson and colleagues at Skåne University Hospital and Hallands Hospital, the paper also includes co-first author Yilun Chen, and Anthony George, Robert Rigo, and Lao Saal participating from SAGA. The paper demonstrates the potential for SAGAsafe to detect subclonal MRD that is missed by conventional flow cytometric determination of residual disease. Read more at https://doi.org/10.1080/10428194.2020.1755855
The SAGAsafe® technology (formerly known as IBSAFE®) is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify mutations in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance to a limit of detection of ~0.001% mutant allele frequency.
SAGAsafe® is part of a portfolio of ultrasensitive technologies, which also includes SAGAsign® (formerly known as KROMA™) for monitoring chromosomal rearrangements, as well as novel technologies in development. SAGA offers both off-the-shelf analysis services and kits as well as custom-tailored solutions to fit customers’ needs. SAGA’s molecular tools are being used in clinical trials and hospitals for detecting actionable mutations, monitoring treatment response, measuring minimal residual disease, and identifying resistance mechanisms to help direct therapy.
Contact: CEO Lao Saal, MD PhD. email@example.com Phone: +46 (0) 733 01 7242
About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.